Niagen Bioscience price to book ratio NAGE

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 2.3×
10-year median: 8.1×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.3× to 48.4×
Peer median: 1.7×

Niagen Bioscience's price to book ratio is 2.3× as of Oct 23, 2026.

That is below its ten-year median of 8.1×, lower than on 100% of days in the last ten years.

Over that time it ranged from 2.3× in Oct 2026 to 48.4× in Mar 2021.

The median for 4 chemicals stocks of a similar size is 1.7×.

Price to book ratio over time

median 8.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.3×	2.3×	7.4×
2025	7.5×	7.3×	20.2×
2024	12.3×	3.9×	17.2×
2023	3.9×	3.4×	7.8×
2022	6.0×	3.8×	6.7×
2021	7.2×	7.2×	48.4×
2020	15.2×	7.8×	19.3×
2019	9.8×	5.5×	15.9×
2018	5.6×	3.8×	9.0×
2017	8.4×	5.8×	16.2×
2016	10.6×	7.2×	37.0×
2015	30.7×	20.2×	41.4×
2014	21.8×	21.8×	65.8×
2013	51.3×	9.2×	51.3×
2012	9.9×	6.0×	25.9×
2011	8.8×	8.8×	17.6×

Against its peers

Companies in Chemicals nearest Niagen Bioscience's size, closest first, today.

Company	Price to book ratio
NAGENiagen Bioscience	2.3×
FTLFFitlife Brands	1.7×
FTKFlotek Industries	6.7×
BTMDbiote	n/m
CRONCronos	1.2×
Peer median	1.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Niagen Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.